(metastasized) prostate cancer (gemetastaseerde) prostaatkanker
Conditions
Interventions
Part A procedure consists of a 10 min PET study after intravenous (iv) administration of H215O, followed by a second 60 min PET study directly after [18F]PSMA administration. The procedure then includ
Sponsors
VU University Medical Center, Amsterdam
Eligibility
Inclusion criteria
Inclusion criteria: Part A • Histologically proven prostate cancer, with lymphatic and/or haematogeneous metastases • Written informed consent • Per patient at least two metastases in the thorax, detected by conventional imaging (e.g., bone scan, either CT or MRI of the chest, abdomen and pelvis); conventional imaging should be recently performed (no longer than 3 months previous to the PET-CT scan) • Diameter of one thoracic metastasis at least  1.5 cm (to minimize partial volume effects) • Patients able to remain supine for 90 minutes in the PET-CT scanner Part B • Histologically proven prostate cancer, with lymphatic and/or haematogeneous metastasis • Written informed consent • At least one metastasis (not necessarily thoracic) with diameter  1.5 cm detected by recently performed conventional imaging (maximal 3 months prior to the PET-CT scan) • Patients able to remain supine for (maximum) 90 minutes in the PET-CT scanner
Exclusion criteria
Exclusion criteria: • Claustrophobia (part A and B) • Multiple malignancies (part A and B) • Participation in part A (part B)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part A: A pharmacokinetic model for [18F]PSMA ([18F]DCFPyl) and a validated simplified quantitative method for [18F]PSMA PET-CT. Part B: Test-retest variability of the derived simplified method (Part A). | — |
Contacts
Public ContactBernard Jansen
Outcome results
None listed